MedTrace Logo

Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)

NCT02350218 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2018-07-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate superiority of Eglandin® (Alprostadil) 720㎍compared to 360㎍ in terms of safety, efficacy in living donor liver transplant patient, peak AST levels followed by Eglandin administration were assessed.

Conditions

  • Evidence of Liver Transplantation

Interventions

DRUG

Eglandin

Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Giwon Song, Professor · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02350218 on ClinicalTrials.gov